The reproducibility of PD-L1 scoring in lung cancer: can the pathologists do better?
作者信息
Troncone Giancarlo, Gridelli Cesare
机构信息
Department of Public Health, University of Naples Federico II, Naples, Italy.
Division of Medical Oncology, "S.G. Moscati" Hospital, Avellino, Italy.
出版信息
Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S74-S77. doi: 10.21037/tlcr.2017.10.05.
Abstract
摘要
相似文献
1
The reproducibility of PD-L1 scoring in lung cancer: can the pathologists do better?
Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S74-S77. doi: 10.21037/tlcr.2017.10.05.
2
A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer.
Appl Immunohistochem Mol Morphol. 2019 Apr;27(4):263-269. doi: 10.1097/PAI.0000000000000737.
3
Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer.
Clin Cancer Res. 2017 Aug 15;23(16):4569-4577. doi: 10.1158/1078-0432.CCR-17-0151. Epub 2017 Apr 18.
4
Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists.
J Pathol Transl Med. 2019 Nov;53(6):347-353. doi: 10.4132/jptm.2019.09.29. Epub 2019 Oct 28.
5
Multicentre study on the consistency of PD-L1 immunohistochemistry as predictive test for immunotherapy in non-small cell lung cancer.
J Clin Pathol. 2020 Jul;73(7):423-430. doi: 10.1136/jclinpath-2019-205993. Epub 2019 Dec 10.
6
Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record.
Cancers (Basel). 2020 Jul 5;12(7):1800. doi: 10.3390/cancers12071800.
7
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Diagn Pathol. 2016 Oct 8;11(1):95. doi: 10.1186/s13000-016-0545-8.
8
Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society.
Arch Pathol Lab Med. 2016 Apr;140(4):341-4. doi: 10.5858/arpa.2015-0506-SA. Epub 2016 Jan 18.
9
[PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists].
Ann Pathol. 2018 Apr;38(2):110-125. doi: 10.1016/j.annpat.2018.01.007. Epub 2018 Mar 21.
10
PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation.
Virchows Arch. 2020 Feb;476(2):243-250. doi: 10.1007/s00428-019-02653-2. Epub 2019 Aug 28.
引用本文的文献
1
PD-L1 Scoring Models for Non-Small Cell Lung Cancer in China: Current Status, AI-Assisted Solutions and Future Perspectives.
Thorac Cancer. 2025 Apr;16(7):e70042. doi: 10.1111/1759-7714.70042.
2
Current Biomarkers in Non-Small Cell Lung Cancer-The Molecular Pathologist's Perspective.
Diagnostics (Basel). 2025 Mar 5;15(5):631. doi: 10.3390/diagnostics15050631.
3
Correlation Between ImageJ and Conventional Manual Scoring Methods for Programmed Death-Ligand 1 Immuno-Histochemically Stained Sections.
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241242635. doi: 10.1177/15330338241242635.
4
Companion diagnostic requirements for spatial biology using multiplex immunofluorescence and multispectral imaging.
Front Mol Biosci. 2023 Feb 9;10:1051491. doi: 10.3389/fmolb.2023.1051491. eCollection 2023.
5
Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise.
Diagnostics (Basel). 2022 Jan 6;12(1):124. doi: 10.3390/diagnostics12010124.
6
Multiplex Immunofluorescence and Multispectral Imaging: Forming the Basis of a Clinical Test Platform for Immuno-Oncology.
Front Mol Biosci. 2021 Jun 2;8:674747. doi: 10.3389/fmolb.2021.674747. eCollection 2021.
7
Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression.
Head Neck Pathol. 2020 Dec;14(4):951-965. doi: 10.1007/s12105-020-01163-x. Epub 2020 Apr 29.
8
Age and sex have no impact on expression levels of markers of immune cell infiltration and immune checkpoint pathways in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy.
Cancer Immunol Immunother. 2019 Jun;68(6):991-997. doi: 10.1007/s00262-019-02340-w. Epub 2019 Apr 17.
9
Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression.
J Cancer. 2019 Jan 1;10(1):211-222. doi: 10.7150/jca.26444. eCollection 2019.
10
Precision immunoprofiling by image analysis and artificial intelligence.
Virchows Arch. 2019 Apr;474(4):511-522. doi: 10.1007/s00428-018-2485-z. Epub 2018 Nov 23.
本文引用的文献
1
FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.
Oncologist. 2017 Nov;22(11):1392-1399. doi: 10.1634/theoncologist.2017-0078. Epub 2017 Aug 23.
2
ALK and ROS1 testing on lung cancer cytologic samples: Perspectives.
Cancer Cytopathol. 2017 Nov;125(11):817-830. doi: 10.1002/cncy.21899. Epub 2017 Jul 25.
3
Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology.
Transl Lung Cancer Res. 2017 Jun;6(3):373-386. doi: 10.21037/tlcr.2017.05.09.
4
PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability.
Mod Pathol. 2017 Oct;30(10):1411-1421. doi: 10.1038/modpathol.2017.59. Epub 2017 Jun 30.
5
Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer.
Clin Cancer Res. 2017 Aug 15;23(16):4569-4577. doi: 10.1158/1078-0432.CCR-17-0151. Epub 2017 Apr 18.
6
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.
JAMA Oncol. 2017 Aug 1;3(8):1051-1058. doi: 10.1001/jamaoncol.2017.0013.
7
Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer.
Mod Pathol. 2017 Mar;30(3):340-349. doi: 10.1038/modpathol.2016.186. Epub 2016 Nov 11.
8
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas.
Mod Pathol. 2016 Oct;29(10):1165-72. doi: 10.1038/modpathol.2016.117. Epub 2016 Jul 8.
9
Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer.
Appl Immunohistochem Mol Morphol. 2016 Jul;24(6):392-7. doi: 10.1097/PAI.0000000000000408.
10
Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC.
Expert Rev Mol Diagn. 2016;16(2):131-3. doi: 10.1586/14737159.2016.1117389. Epub 2015 Nov 27.
Zotero 插件